Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. It offers medical care and supplemental benefit plans to individuals. The company also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, it provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; and military services, such as TRICARE T2017 East Region contract. Further, the company engages in the operation of pharmacy benefit manager business; operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. It sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Humana Inc.

Analysts are intrested in these 5 stocks: ( ($MNDY) ), ( ($HUM) ), ( ($MP) ) and ( ($OKLO) ). Here is a breakdown of their recent ratings and the


Monday.com, Humana, MP, Oklo: Trending by Analysts

The latest announcement is out from Humana ( ($HUM) ). Humana Inc. announced that its senior management will meet with investors and analysts throu...

Humana Reaffirms Earnings Guidance for December 2025

Hua Medicine ( ($HK:2552) ) has shared an update. Hua Medicine announced the grant of 20 million share options to three executive directors and 71 ...

Hua Medicine Grants Share Options to Drive Growth and Commitment

In a report released today, Andrew Mok CFA from Barclays maintained a Hold rating on Humana, with a price target of $234.00. Mok CFA covers the Hea...

Barclays Remains a Hold on Humana (HUM)

Benchmark Co. analyst Bruce Jackson maintained a Buy rating on Humacyte yesterday and set a price target of $11.00. The company’s shares closed yes...

Benchmark Co. Keeps Their Buy Rating on Humacyte (HUMA)

Humm Group Limited ( ($AU:HUM) ) just unveiled an update. Humm Group Limited has announced the issuance of 7,025,995 ordinary fully paid shares to ...

Humm Group Issues Shares for Employee Incentive Plan

Humm Group Limited ( ($AU:HUM) ) has provided an update. Humm Group Limited has issued 7,025,995 fully paid ordinary shares to the trustee of its E...

Humm Group Enhances Employee Incentive Plan with New Share Issuance

An update from Humm Group Limited ( ($AU:HUM) ) is now available. At its 2025 Annual General Meeting, humm Group Limited announced the results of i...

humm Group Faces Shareholder Dissent at 2025 AGM

Humm Group Limited ( ($AU:HUM) ) has issued an update. Humm Group Limited received a non-binding indicative proposal from The Abercrombie Group Pty...

Humm Group Evaluates Acquisition Proposal Amidst Shareholder Scrutiny

An announcement from Humm Group Limited ( ($AU:HUM) ) is now available. Humm Group Limited’s FY25 results highlight a 10% increase in assets under ...

Market Cap	$34.12B	P/E Ratio	15.51
52W High	$315.35	52W Low	$206.87
Div Yield	354.0%	Payout Ratio	34.8%
EPS Growth 3Y	N/A	52W Position	53.6%
Overall Score	62	Value Score	100
Quality Score	55	Technical Score	33

EPS Current Est	$17.08	EPS Next Est	$12.19
EPS Growth Est	-28.6%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	HUM	$264.98	+3.24%	1.26M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	HUM	$264.98	+3.2%	1.26M
3
4
5
6

HUM

HUM

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Humana Inc. Data in Excel

Get Humana Inc. Data in Excel